Dive Brief:
- Kandu Health and Neurolutions have recently announced their merger and successful fundraising of $30 million to advance stroke recovery and rehabilitation initiatives.
- This collaboration combines Neurolutions’ innovative brain computer interface technology with Kandu Health’s telehealth services to enhance the outcomes of stroke patients post-hospital discharge.
- Patients will now have access to Neurolutions’ IpsiHand device, which has received clearance for use in the United States. This system enables stroke survivors to control the opening and closing of their hands through brain signal translation.
Dive Insight:
Neurolutions obtained de novo authorization for its IpsiHand device in 2021. The technology comprises a headset, a tablet, and a wearable hand and wrist device. By recording brain activity using non-invasive electroencephalography electrodes, the system interprets the data to facilitate hand movements based on the user’s brain signals, aiding in stroke recovery.
The FDA approval was granted following a successful 12-week trial involving 40 patients, all of whom demonstrated significant motor function improvements using the IpsiHand system.
Kandu Health, established in 2022, formed a strategic partnership with Neurolutions in 2023 to integrate the IpsiHand technology into its stroke rehabilitation programs.
Furthermore, the Centers for Medicare & Medicaid Services (CMS) introduced a unique procedure code and benefit category determination for IpsiHand in 2024, marking a milestone in reimbursement and accessibility for stroke patients.
CEO Kirsten Carroll emphasized the significance of IpsiHand as the first FDA-cleared BCI technology for stroke rehabilitation with a CMS reimbursement code, distinguishing it from other invasive brain implant technologies.
With a focus on improving post-stroke quality of life, Kandu aims to provide comprehensive support services through the integration of IpsiHand, addressing the ongoing needs of stroke survivors throughout their recovery journey.
Investors Ally Bridge Group and Amed Ventures co-led the $30 million funding round to bolster Kandu’s commercial strategy and expand access to innovative stroke rehabilitation solutions.
